Howard Horn serves as the Chief Financial Officer, Corporate Strategy, and Executive Vice President at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases. In his role, Horn is responsible for overseeing the financial strategy, corporate planning, and investor relations of the company. His leadership has been instrumental in guiding Ultragenyx through various stages of growth and development, ensuring the company remains financially robust while pursuing its mission to bring life-changing therapies to patients. Prior to joining Ultragenyx, Howard Horn held several key positions in the biopharmaceutical industry, showcasing his extensive experience and expertise in financial management and strategic planning. He previously served as the Chief Financial Officer at BioMarin Pharmaceutical Inc., where he played a pivotal role in the company's financial operations and growth strategies. Horn's career also includes significant roles at other notable organizations such as Chiron Corporation and J.P. Morgan Securities Inc., where he honed his skills in investment banking and corporate finance. His background in both the financial and healthcare sectors has equipped him with a unique perspective, enabling him to effectively navigate the complexities of the biopharmaceutical industry. Horn's achievements at Ultragenyx include leading the company through successful financings and strategic partnerships that have bolstered its ability to advance its pipeline of innovative therapies. Under his guidance, Ultragenyx has achieved several milestones, including the commercialization of its first product, Crysvita, and the continued development of its diverse portfolio of treatments for rare diseases. Horn's strategic vision and financial acumen continue to be vital assets for Ultragenyx as it strives to expand its reach and impact in the global healthcare landscape.